CVS slides as Medicare Advantage reimbursement outlook weighs on managed-care sentiment

CVS Health (CVS) is down 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks tied to renewed investor focus on Medicare Advantage reimbursement pressure, which can squeeze margins at CVS’s Aetna insurance unit. Ongoing concern around policy-driven rate tightening and risk-adjustment changes appears to be weighing on managed-care names even in the absence of CVS-specific breaking news.

Details:

Federal Medicare officials have proposed a very small net payment update for 2027 Medicare Advantage plans, a setup that can pressure insurers’ profitability and benefit design.

Proposed changes to the risk-adjustment framework (including limiting certain diagnosis additions not tied to direct medical encounters) could reduce reimbursement uplift versus prior practices.

Recent industry data has also pointed to slower Medicare Advantage enrollment growth, reinforcing fears that insurers may have less room to offset cost trends through scale.

Separately, CVS’s most recent full-year outlook included a reduced cash-from-operations expectation versus its prior target, which may have increased sensitivity to any adverse policy headlines.

Sources:

MarketWatch, CVS Health Investor Relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CVS Hedge Fund Activity

We have seen 867 institutional investors add shares of $CVS stock to their portfolio, and 959 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 23,387,155 shares (-73.8%) from their portfolio in Q4 2025, for an estimated $1,856,004,620
WELLINGTON MANAGEMENT GROUP LLP added 12,233,675 shares (+193.2%) to their portfolio in Q4 2025, for an estimated $970,864,448
DODGE & COX removed 10,666,598 shares (-14.6%) from their portfolio in Q4 2025, for an estimated $846,501,217
DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 8,355,230 shares (+822.1%) to their portfolio in Q4 2025, for an estimated $663,071,052
JPMORGAN CHASE & CO removed 4,072,568 shares (-11.5%) from their portfolio in Q4 2025, for an estimated $323,198,996
MARSHALL WACE, LLP removed 3,649,256 shares (-99.6%) from their portfolio in Q4 2025, for an estimated $289,604,956
FRANKLIN RESOURCES INC removed 3,438,834 shares (-47.8%) from their portfolio in Q4 2025, for an estimated $272,905,866

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CVS Government Contracts

We have seen $7,069,230 of award payments to $CVS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EFFECTIVENESS AND SAFETY (BES...: $5,476,406
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EFFECTIVENESS AND SAFETY (BES...: $1,381,573
PHARMACY REPACKAGING: $200,000
CVS GIFT CARDS: $11,250

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$CVS Congressional Stock Trading

Members of Congress have traded $CVS stock 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $CVS stock by members of Congress over the last 6 months:

SENATOR JOHN BOOZMAN purchased up to $15,000 on 01/29.
REPRESENTATIVE DWIGHT EVANS sold up to $15,000 on 11/21.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$CVS Analyst Ratings

Wall Street analysts have issued reports on $CVS in the last several months. We have seen 12 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 12/10/2025
Piper Sandler issued a "Overweight" rating on 12/10/2025
UBS issued a "Buy" rating on 12/10/2025
Barclays issued a "Overweight" rating on 12/10/2025
Mizuho issued a "Outperform" rating on 12/10/2025
Wells Fargo issued a "Overweight" rating on 11/13/2025
TD Cowen issued a "Buy" rating on 11/03/2025

To track analyst ratings and price targets for $CVS, check out Quiver Quantitative's $CVS forecast page.

$CVS Price Targets

Multiple analysts have issued price targets for $CVS recently. We have seen 17 analysts offer price targets for $CVS in the last 6 months, with a median target of $95.0.

Here are some recent targets:

Steve Silver from Argus Research set a target price of $90.0 on 01/28/2026
Michael Cherny from B of A Securities set a target price of $95.0 on 01/27/2026
Lisa Gill from JP Morgan set a target price of $101.0 on 12/17/2025
Lance Wilkes from Bernstein set a target price of $87.0 on 12/12/2025
Michael Ha from Baird set a target price of $92.0 on 12/10/2025
Kevin Caliendo from UBS set a target price of $97.0 on 12/10/2025
Andrew Mok from Barclays set a target price of $93.0 on 12/10/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.